Kinase Signalling in Huntington's Disease

Journal of Huntington's Disease

Volumn 3, Issue 2, 2014, Pages 89-123

  Bowles, Kathryn R ^a   Jones, Lesley ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

AKT; CDK5 P35; Huntington's disease; IKK; inflammation; kinase signalling; MAPKs; MEK ERK; P53; pro apoptotic; pro survival

Indexed keywords

CYCLIN DEPENDENT KINASE 5; GROWTH FACTOR; HUNTINGTIN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN P35; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE;

ENZYME PHOSPHORYLATION; HUMAN; HUNTINGTON CHOREA; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; AKT; ANIMAL; APOPTOSIS; CDK5/P35; DISEASE MODEL; IKK; INFLAMMATION; KINASE SIGNALLING; MAPKS; MEK/ERK; METABOLISM; PATHOLOGY; PHYSIOLOGY; PRO-APOPTOTIC; PRO-SURVIVAL;

AKT; CDK5/P35; HUNTINGTON'S DISEASE; IKK; INFLAMMATION; KINASE SIGNALLING; MAPKS; MEK/ERK; P53; PRO-APOPTOTIC; PRO-SURVIVAL;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; MAP KINASE SIGNALING SYSTEM;

EID: 84907202379     PISSN: 18796397     EISSN: 18796400     Source Type: Journal    
DOI: 10.3233/JHD-140106     Document Type: Review

References (296)

1. Martin JB, Gusella JF, Ronthal M, Herzog A, Flier JS, Amir S. Huntington's Disease-Pathogenesis and management. N Engl J Med. 1986;315(20):1267-76.
2. Myers RH, Sax DS, Schoenfeld M, Bird ED,Wolf PA, Vonsattel JP, White RF, Martin JB. Late onset of Huntington's disease. J Neurol Neurosurg Psychiatry. 1985;48(6):530-4.
3. Novak MJU, Tabrizi SJ. Huntington's disease. BMJ. 2010;341(c3109):34-40.
4. Vonsattel JPG, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol. 1998;57(5):369-84.
5. Wexler NS. Huntington's disease: Advocacy driving science. Annu Rev Med. 2012;63:1-22.
6. Politis M, Pavese N, Tai YF, Tabrizi SJ, Barker RA, Piccini P. Hypothalamic involvement in Huntingtons disease: An in vivo PET study. Brain. 2008;131(11):2860-9.
7. Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone N, Hersch SM. Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity. Brain. 2008;131(4):1057-68.
8. Scahill RI, Hobbs NZ, Say MJ, Bechtel N, Henley SMD, Hyare H, Langbehn DR, Jones R, Leavitt BR, Roos R a C, Durr A, Johnson H, Lehéricy S, Craufurd D, Kennard C, Hicks SL, Stout JC, Reilmann R, Tabrizi SJ. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum Brain Mapp. 2013;34(3):519-29.
9. DiFiglia M. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277(5334):1990-3.
10. Gomez-Tortosa E, MacDonald ME, Friend JC, Taylor SAM, Weiler LJ, Cupples LA, Srinidhi J, Gusella JF, Bird ED, Vonsattel JP, Myers RH. Quantitative neuropathological changes in presymptomatic Huntington's disease. Ann Neurol. 2001;49(1):29-34.
11. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431(7010):805-10.
12. Tsvetkov AS, Arrasate M, Barmada S, Ando DM, Sharma P, Shaby BA, Finkbeiner S. Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration. Nat Chem Biol. 2013;9(9):586-92.
13. Besant PG, Tan E, Attwood PV. Mammalian protein histidine kinases. Int J Biochem Cell Biol. 2003;35(3):297-309.
14. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):1912-34.
15. Ginés S, Ivanova E, Seong I-S, Saura CA, MacDonald ME. Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. J Biol Chem. 2003;278(50):50514-22.
16. Ginés S, Paoletti P, Alberch J. Impaired TrkB-mediated ERK1/2 activation in huntington disease knock-in striatal cells involves reduced p52/p46 Shc expression. J Biol Chem. 2010;285(28):21537-48.
17. Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee R V, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, Moller T, Tabrizi SJ. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med. 2008;205(8):1869-77.
18. Hsiao H-Y, Chen Y-C, Chen H-M, Tu P-H, Chern Y. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease. Hum Mol Genet. 2013;22(9):1826-42.
19. Mattson MP. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. Antioxid Redox Signal. 2006;8(11-12):1997-2006.
20. Bowles KR, Brooks SP, Dunnett SB, Jones L. Gene expression and behaviour in mouse models of HD. Brain Res Bull. 2012;88(2-3):276-84.
21. Crocker SF, Costain WJ, Robertson HA. DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations. Brain Res. 2006;1088(1): 176-86.
22. Crook ZR, Housman D. Huntington's disease: Can mice lead the way to treatment? Neuron. 2011;69(3):423-35.
23. Ross CA. Polyglutamine pathogenesis: Emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron. 2002;35(5):819-22.
24. Seredenina T, Luthi-Carter R. What have we learned from gene expression profiles in Huntington's disease? Neurobiol Dis. 2012;45(1):83-98.
25. Zucker B, Luthi-Carter R, Kama J a, Dunah AW, Stern E a, Fox JH, Standaert DG, Young AB, Augood SJ. Transcriptional dysregulation in striatal projection-and interneurons in a mouse model of Huntington's disease: Neuronal selectivity and potential neuroprotective role of HAP1. Hum Mol Genet. 2005;14(2):179-89.
26. Apostol BL, Illes K, Pallos J, Bodai L, Wu J, Strand A, Schweitzer ES, Olson JM, Kazantsev A, Marsh JL, Thompson LM. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet. 2006;15(2):273-85.
27. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, Bourguignon L, Hung MC. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol. 2001;3(9):802-8.
28. Cabodi S, Morello V, Masi A, Cicchi R, Broggio C, Distefano P, Brunelli E, Silengo L, Pavone F, Arcangeli A, Turco E, Tarone G, Moro L, Defilippi P. Convergence of integrins and EGF receptor signaling via PI3K/Akt/FoxO pathway in early gene Egr-1 expression. J Cell Physiol. 2009;218(2):294-303.
29. Kong P-J, Kil M-O, Lee H, Kim S-S, Johnson GVW, Chun W. Increased expression of Bim contributes to the potentiation of serum deprivation-induced apoptotic cell death in Huntington's disease knock-in striatal cell line. Neurol Res. 2009;31(1):77-83.
30. Ro Y-T, Jang B-K, Shin CY, Park EU, Kim CG, Yang S-I. Akt regulates the expression of MafK, synaptotagmin I, and syntenin-1, which play roles in neuronal function. J Biomed Sci. 2010;17:18.
31. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev. 2004;68(2):320-44.
32. Miloso M, Scuteri A, Foudah D, Tredici G.MAPKsas mediators of cell fate determination: An approach to neurodegenerative diseases. Curr Med Chem. 2008;15(6):538-48.
33. Roze E, Betuing S, Deyts C, Marcon E, Brami-Cherrier K, Pagès C, Humbert S,Mérienne K, Caboche J. Mitogen-and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death. FASEB J. 2008;22(4):1083-93.
34. Xuan Nguyen T Le, Choi JW, Lee SB, Ye K,Woo S-D, Lee K-H, Ahn J-Y. Akt phosphorylation is essential for nuclear translocation and retention in NGF-stimulated PC12 cells. Biochem Biophys Res Commun. 2006;349(2):789-98.
35. Gallo KA, Johnson GL. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol. 2002;3(9):663-72.
36. Cheng Q, Chen L, Li Z, LaneWS,Chen J.ATMactivates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J. 2009;28(24):3857-67.
37. Bodai L, Marsh JL. A novel target for Huntington's disease: ERK at the crossroads of signaling. Bio Essays. 2012;34(2):142-8.
38. Ebisuya M, Kondoh K, Nishida E. The duration, magnitude and compartmentalization of ERK MAP kinase activity: Mechanisms for providing signaling specificity. J Cell Sci. 2005;118(Pt 14):2997-3002.
39. Kim J-Y, Kim Y-J, Lee S, Park J-H. The critical role of ERK in death resistance and invasiveness of hypoxia-selected glioblastoma cells. BMC Cancer. 2009;9:27.
40. Roskoski R. MEK1/2 dual-specificity protein kinases: Structure and regulation. Biochem Biophys Res Commun. 2012;417(1):5-10.
41. Hetman M, Gozdz A. Role of extracellular signal regulated kinases 1 and 2 in neuronal survival. Eur J Biochem. 2004;271(11):2050-5.
42. Singer CA, Figueroa-Masot XA, Batchelor RH, Dorsa DM. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J Neurosci. 1999;19(7):2455-63.
43. Anglada-Huguet M, Giralt A, Perez-Navarro E, Alberch J, Xifró X. Activation of Elk-1 participates as a neuroprotective compensatory mechanism in models of Huntington's disease. J Neurochem. 2012;121(4):639-48.
44. Biswas SC, Greene LA. Nerve growth factor (NGF) downregulates the Bcl-2 homology 3 (BH3) domain-only protein Bim and suppresses its proapoptotic activity by phosphorylation. J Biol Chem. 2002;277(51):49511-6.
45. Ley R, Ewings KE, Hadfield K, Howes E, Balmanno K, Cook SJ. Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem. 2004;279(10):8837-47.
46. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation ofNIH3T3 cells. Cell. 1994;77(6):841-52.
47. Pang L, Zheng CF, Guan KL, Saltiel AR. Nerve growthfactor stimulates a novel protein-kinase in PC-12 cells that phosphorylates and activates mitogen-activated proteinkinase kinase (MEK). Biochem J. 1995;307(2):513-9.
48. Segal RA, Greenberg ME. Intracellular signaling pathways activated by neurotrophic factors. Annu Rev Neurosci. 1996;19:463-89.
49. Li X, Newbern JM,Wu Y,Morgan-Smith M, Zhong J, Charron J, Snider WD. MEK is a key regulator of gliogenesis in the developing brain. Neuron. 2012;75(6):1035-50.
50. Gokce O, Runne H,Kuhn A, Luthi-Carter R. Short-term striatal gene expression responses to brain-derived neurotrophic factor are dependent on MEK and ERK activation. PLoS One. 2009;4(4):e5292.
51. Liebelt B, Papapetrou P, Ali A, Guo M, Ji X, Peng C, Rogers R, Curry A, Jimenez D, Ding Y. Exercise preconditioning reduces neuronal apoptosis in stroke by up-regulating heat shock protein-70 (heat shock protein-72) and extracellular-signal-regulated-kinase 1/2. Neuroscience. 2010;166(4):1091-100.
52. Yu C-G, Yezierski RP, Joshi A, Raza K, Li Y, Geddes JW. Involvement of ERK2 in traumatic spinal cord injury. J Neurochem. 2010;113(1):131-42.
53. Colucci-D'Amato L, Perrone-Capano C, di Porzio U. Chronic activation of ERK and neurodegenerative diseases. BioEssays. 2003;25(11):1085-95.
54. Stanciu M. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem. 2000;275(16):12200-6.
55. Zhu J-H, Kulich SM, Oury TD, Chu CT. Cytoplasmic aggregates of phosphorylated extracellular signal-regulated protein kinases in Lewy body diseases. Am J Pathol. 2002;161(6):2087-98.
56. DineleyKT,Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci. 2001;21(12):4125-33.
57. Chu CT, Levinthal DJ, Kulich SM, Chalovich EM, DeFranco DB. Oxidative neuronal injury. The dark side of ERK1/2. Eur J Biochem. 2004;271(11):2060-6.
58. Fusco FR, Anzilotti S, Giampá C, Dato C, Laurenti D, Leuti A, Colucci D'Amato L, Perrone L, Bernardi G, Melone MAB. Changes in the expression of extracellular regulated kinase (ERK 1/2) in the R6/2 mouse model of Huntington's disease after phosphodiesterase IV inhibition. Neurobiol Dis. 2012;46(1):225-33.
59. Saavedra A, Giralt A, Rué L, Xifró X, Xu J, Ortega Z, Lucas JJ, Lombroso PJ, Alberch J, Pérez-Navarro E. Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: A STEP in the resistance to excitotoxicity. J Neurosci. 2011;31(22):8150-62.
60. Luo S, Vacher C, Davies JE, Rubinsztein DC. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: Implications for mutant huntingtin toxicity. J Cell Biol. 2005;169(4):647-56.
61. Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, Warby SC, Doty CN, Roy S,Wellington CL, Leavitt BR, Raymond LA, Nicholson DW, Hayden MR. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006;125(6):1179-91.
62. Warby SC, Doty CN, Graham RK, Shively J, Singaraja RR, Hayden MR. Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments. Mol Cell Neurosci. 2009;40(2):121-7.
63. Liévens J-C, Rival T, Iché M, Chneiweiss H, Birman S. Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum Mol Genet. 2005;14(5):713-24.
64. Mazarakis NK, Cybulska-Klosowicz A, Grote H, Pang T, Van Dellen A, Kossut M, Blakemore C, Hannan AJ. Deficits in experience-dependent cortical plasticity and sensorydiscrimination learning in presymptomatic Huntington's disease mice. J Neurosci. 2005;25(12):3059-66.
65. Cowin R-M, Bui N, Graham D, Green JR, Grueninger S, Yuva-Paylor La, Syed AU, Weiss A, Paylor R. Onset and progression of behavioral and molecular phenotypes in a novel congenic R6/2 line exhibiting intergenerational CAG repeat stability. PLoS One. 2011;6(12):e28409.
66. Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, Dunnett SB. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci. 1999;19(23):10428-37.
67. Cayzac S, Delcasso S, Paz V, Jeantet Y, Cho YH. Changes in striatal procedural memory coding correlate with learning deficits in a mouse model of Huntington disease. Proc Natl Acad Sci U S A. 2011;108(22):9280-5.
68. Brooks SP, Janghra N, Workman VL, Bayram-Weston Z, Jones L, Dunnett SB. Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic mice. Brain Res Bull. 2012;88(2-3):94-103.
69. Liot G, Zala D, Pla P, Mottet G, Piel M, Saudou F. Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J Neurosci. 2013;33(15):6298-309.
70. Baksi S, Jana NR, Bhattacharyya NP, Mukhopadhyay D. Grb2 is regulated by foxd3 and has roles in preventing accumulation and aggregation of mutant huntingtin. PLoS One. 2013;8(10):e76792.
71. Giralt A, Rodrigo T, Martín ED, Gonzalez JR, Milá M, Ceña V, Dierssen M, Canals JM, Alberch J. Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: Involvement of phospholipaseCgamma activity and glutamate receptor expression. Neuroscience. 2009;158(4):1234-50.
72. Lievens J. Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Mol Cell Neurosci. 2002;20(4):638-48.
73. Gianfriddo M, Melani A, Turchi D, Giovannini MG, Pedata F. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol Dis. 2004;17(1):77-88.
74. Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, Cordelieres FP, De Mey J, MacDonald ME, Lessmann V, Humbert S, Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004;118(1):127-38.
75. Baquet ZC, Gorski JA, Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci. 2004;24(17):4250-8.
76. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol. 2007;81(5-6):294-330.
77. Iijima-ando K, Wu P, Drier EA, Iijima K, Yin JCP. cAMPresponse element-binding protein and heat-shock protein 70 additively suppress polyglutamine-mediated toxicity in Drosophila. Proc Natl Acad SciUSA. 2005;102(29):10261-6.
78. Liévens J-C, Iché M, Laval M, Faivre-Sarrailh C, Birman S. AKT-sensitive or insensitive pathways of toxicity in glial cells and neurons in Drosophila models of Huntington's disease. Hum Mol Genet. 2008;17(6):882-94.
79. Maher P, Dargusch R, Bodai L, Gerard PE, Purcell JM, Marsh JL. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum Mol Genet. 2011;20(2): 261-70.
80. Scotter EL, Goodfellow CE, Graham ES, Dragunow M, Glass M. Neuroprotective potential ofCB1receptor agonists in an in vitro model of Huntington's disease. Br J Pharmacol. 2010;160(3):747-61.
81. Zhang JH, Zhang DS, McQuade JS, Behbehani M, Tsien JZ, XuM.C-fos regulates neuronal excitability and survival. Nat Genet. 2002;30(4):416-20.
82. Vanhoutte P, Barnier J, Guibert B, Pagès C, Besson M, Hipskind RA, Page C, Caboche J. Glutamate induces phosphorylation of Elk-1 and CREB, along with c-fos activation, via an extracellular pathway in brain slices glutamate induces phosphorylation of Elk-1 and CREB, along with c-fos activation, via an extracellular signal-regulated Ki. Mol Cell Biol. 1999;19(1):136-46.
83. Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogenand stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 1998;17(15):4426-41.
84. Soloaga A, Thomson S, Wiggin GR, Rampersaud N, Dyson MH, Hazzalin C a, Mahadevan LC, Arthur JSC. MSK2 and MSK1 mediate the mitogen-and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J. 2003;22(11):2788-97.
85. Song C, Perides G, Liu YF. Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells. J Biol Chem. 2002;277(8):6703-7.
86. Colin E, Régulier E, Perrin V, Dürr A, Brice A, Aebischer P, Déglon N, Humbert S, Saudou F. Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci. 2005;21(6):1478-88.
87. Liu YF, Deth RC, Devys D. SH3 domain-dependent association of Huntingtin with epidermal growth factor receptor signaling complexes. J Biol Chem. 1997;272(13):8121-4.
88. Humbert S. Huntingtin phosphorylation and signaling pathways that regulate toxicity in Huntington's disease. Clin Neurosci Res. 2003;3(3):149-55.
89. Miaczynska M, Pelkmans L, Zerial M. Not just a sink: Endosomes in control of signal transduction. Curr Opin Cell Biol. 2004;16(4):400-6.
90. Melone MAB, Calarco A, Petillo O, Margarucci S, Colucci-D'Amato L, Galderisi U, Koverech G, Peluso G. Mutant huntingtin regulates EGF receptor fate in non-neuronal cells lacking wild-type protein. Biochim Biophys Acta. 2013;1832(1):105-13.
91. Brito V, Puigdellivol M, Giralt A, del Toro D, Alberch JBS. Imbalance of p75 NTR/TrkB protein expression in Huntington's disease: Implication for neuroprotective therapies. Cell Death Dis. 2013;4(e595):1-15.
92. Ginés S, Bosch M, Marco S, Gavaldá N, Díaz-Hernández M, Lucas JJ, Canals JM, Alberch J. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur J Neurosci. 2006;23(3):649-58.
93. Choi Y, Lin SL, Lee B, Kurup P, Cho H, Janice R, Lombroso PJ, Obrietan K. Status epilepticus-induced somatostatinergic hilar interneuron degeneration is regulated by striatal enriched protein tyrosine phosphatase. J Neurosci. 2007;27(11):2999-3009.
94. Wang P, Li B, Zhou L, Fei E, Wang G. The KDEL receptor induces autophagy to promote the clearance of neurodegenerative disease-related proteins. Neuroscience. 2011;190:43-55.
95. Gu X, Greiner ER, Mishra R, Kodali R, Osmand A, Finkbeiner S, Steffan JS, Thompson LM, Wetzel R, Yang XW. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron. 2009;64(6):828-40.
96. Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JG, Khashwji H, Lukacsovich T, Zhu Y-Z, Lau AL, MasseyA, HaydenMR,Zeitlin SO, Finkbeiner S, Green KN, LaFerla FM, Bates G, Huang L, Patterson PH, Lo DC, Cuervo AM, Marsh JL, Steffan JS. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol. 2009;187(7):1083-99.
97. Atwal RS, Desmond CR, Caron N, Maiuri T, Xia J, Sipione S, Truant R. Kinase inhibitors modulate huntingtin cell localization and toxicity. Nat Chem Biol. 2011;7(7):453-60.
98. Havel LS,Wang C-E,Wade B, Huang B, Li S, Li X-J. Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. Hum Mol Genet. 2011;20(7):1424-37.
99. Atwal RS, Xia J, Pinchev D, Taylor J, Epand RM, Truant R. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum Mol Genet. 2007;16(21):2600-15.
100. Desmond CR, Maiuri T, Truant R. A multifunctional, multipathway intracellular localization signal in Huntingtin. Commun Integr Biol. 2013;6(2):e23318.
101. Khoshnan A, Patterson PH. The role of IκB kinase complex in the neurobiology of Huntington's disease. Neurobiol Dis. 2011;43(2):305-11.
102. Bauer PO, Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem. 2009;110(6):1737-65.
103. Maiuri T, Woloshansky T, Xia J, Truant R. The huntingtin N17 domain is a multifunctional CRM1 and Ran-dependent nuclear and cilial export signal. Hum Mol Genet. 2013;22(7):1383-94.
104. Zala D, Colin E, Rangone H, Liot G, Humbert S, Saudou F. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet. 2008;17(24):3837-46.
105. Schilling B, Gafni J, Torcassi C, Cong X, RowRH, LaFevre-BerntMa, CusackMP, RatovitskiT, Hirschhorn R, RossCa, Gibson BW, Ellerby LM. Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity. J Biol Chem. 2006;281(33):23686-97.
106. Su SC, Tsai L-H. Cyclin-dependent kinases in brain development and disease. Annu Rev Cell Dev Biol. 2011;27:465-91.
107. Tsai LH, Takahashi T, Caviness VS, Harlow E. Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Development. 1993;119(4):1029-40.
108. Harada T, Morooka T, Ogawa S, Nishida E. ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1. Nat Cell Biol. 2001;3(5):453-9.
109. Tokuoka H, Saito T, Yorifuji H, Wei F, Kishimoto T, Hisanaga S. Brain-derived neurotrophic factor-induced phosphorylation of neurofilament-H subunit in primary cultures of embryo rat cortical neurons. J Cell Sci. 2000;113 Pt 6:1059-68.
110. Bogush A, Pedrini S, Pelta-Heller J, Chan T, Yang Q, Mao Z, Sluzas E, Gieringer T, Ehrlich ME. AKT and CDK5/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro. J Biol Chem. 2007;282(10):7352-9.
111. Modi PK, Komaravelli N, Singh N, Sharma P. Interplay between MEK-ERK signaling, cyclin D1, and cyclindependent kinase 5 regulates cell cycle reentry and apoptosis of neurons. Mol Biol Cell. 2012;23(18):3722-30.
112. Sharma P,Veeranna, Sharma M, Amin ND, Sihag RK, Grant P, Ahn N,Kulkarni AB, Pant HC. Phosphorylation ofMEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway. J Biol Chem. 2002;277(1):528-34.
113. Zheng Y, Li B, Kanungo J, Kesavapany S, Amin N, Grant P, Pant HC. Cdk5 modulation of mitogen-activated protein kinase signaling regulates neuronal survival. Mol Biol Cell. 2007;18:404-13.
114. Li B-S, Zhang L, Takahashi S, Ma W, Jaffe H, Kulkarni AB, Pant HC. Cyclin-dependent kinase 5 prevents neuronal apoptosis by negative regulation of c-Jun N-terminal kinase 3. EMBO J. 2002;21(3):324-33.
115. Li B-S, Ma W, Jaffe H, Zheng Y, Takahashi S, Zhang L, Kulkarni AB, Pant HC. Cyclin-dependent kinase-5 is involved in neuregulin-dependent activation of phosphatidylinositol 3-kinase and Akt activity mediating neuronal survival. J Biol Chem. 2003;278(37):35702-9.
116. Cheung ZH, Ip NY. Cdk5: Mediator of neuronal death and survival. Neurosci Lett. 2004;361(1-3):47-51.
117. Dhavan R, Tsai LH. A decade of CDK5. Nat Rev Mol Cell Biol. 2001;2(10):749-59.
118. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402(6762):615-22.
119. Cheung ZH, IpNY. Cdk5:Amultifaceted kinase in neurodegenerative diseases. Trends Cell Biol. 2012;22(3):169-75.
120. Lu T, Pan Y, Kao S, Li C, Kohane I. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429:883-91.
121. Anne SL, Saudou F, Humbert S. Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons. J Neurosci. 2007;27(27):7318-28.
122. Paoletti P, Vila I, Rifé M, Lizcano JM, Alberch J, Ginés S. Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: The role of p25/cyclin-dependent kinase 5. J Neurosci. 2008;28(40): 10090-101.
123. Muchowski PJ, Ning K, D'Souza-Schorey C, Fields S. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc Natl Acad Sci U S A. 2002;99(2): 727-32.
124. Taylor JP. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet. 2003;12(7):749-57.
125. Webb JL, Ravikumar B, Rubinsztein DC. Microtubule disruption inhibits autophagosome-lysosome fusion: Implications for studying the roles of aggresomes in polyglutamine diseases. Int J Biochem Cell Biol. 2004;36(12):2541-50.
126. Kaminosono S, Saito T, Oyama F, Ohshima T, Asada A, Nagai Y, Nukina N, Hisanaga S-I. Suppression of mutant Huntingtin aggregate formation by Cdk5/p35 through the effect on microtubule stability. J Neurosci. 2008;28(35):8747-55.
127. Niethammer M, Smith DS, Ayala R, Peng J, Ko J, Lee MS, Morabito M, Tsai LH. NUDEL is a novel Cdk5 substrate that associates with LIS1 and cytoplasmic dynein. Neuron. 2000;28(3):697-711.
128. Owada Y, Utsunomiya A, Yoshimoto T, Kondo H. Expression of mRNA for Akt, serine-threonine protein kinase, in the brain during development and its transient enhancement following axotomy of hypoglossal nerve. J Mol Neurosci. 1997;9(1):27-33.
129. Noshita N, Lewen A, Sugawara T, Chan PH. Evidence of phosphorylation of Akt and neuronal survival after transient focal cerebral ischemia in mice. J Cerebreal Blood Flow Metab. 2001;21(12):1442-50.
130. Endo H, Nito C, Kamada H, Nishi T, Chan PH. Activation of the Akt/GSK3beta signaling pathway mediates survival of vulnerable hippocampal neurons after transient global cerebral ischemia in rats. J Cereb Blood FlowMetab. 2006;26(12):1479-89.
131. Zhang Y, Leavitt BR, van Raamsdonk JM, Dragatsis I, Goldowitz D, MacDonald ME, Hayden MR, Friedlander RM. Huntingtin inhibits caspase-3 activation. EMBO J. 2006;25(24):5896-906.
132. Hashimoto M, Bar-On P, Ho G, Takenouchi T, Rockenstein E, Crews L, Masliah E. Beta-synuclein regulates Akt activity in neuronal cells.Apossible mechanism for neuroprotection in Parkinson's disease. J Biol Chem. 2004;279(22):23622-9.
133. Burgering BMT, Kops GJPL. Cell cycle and death control: Long live Forkheads. Trends Biochem Sci. 2002;27(7):352-60.
134. Meng F, Liu L, Chin PC, D'Mello SR. Akt is a downstream target of NF-kappa B. J Biol Chem. 2002;277(33):29674-80.
135. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor university of california at san diego. Cell. 1999;96:857-68.
136. Tang ED, Nunez G, Barr FG, Guan K-L. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem. 1999;274(24):16741-6.
137. Humbert S, Bryson EA, Cordelie FP, Connors NC, Datta SR, Finkbeiner S, Greenberg ME, Saudou F. The IGF-1/Akt Pathway is neuroprotective in Huntington's disease and involves huntingtin phosphorylation by Akt. Dev Cell. 2002;2(6):831-7.
138. Bardai FH, D'Mello SR. Selective toxicity by HDAC3 in neurons: Regulation by Akt and GSK3beta. J Neurosci. 2011;31(5):1746-51.
139. Junyent F, de Lemos L,Verdaguer E, PallàsM,Folch J, Beas-Zárate C, Camins A, Auladell C. Lack of Jun-N-terminal kinase 3 (JNK3) does not protect against neurodegeneration induced by 3-nitropropionic acid. Neuropathol Appl Neurobiol. 2012;38(4):311-21.
140. Chong ZZ, Li F, Maiese K. Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol Histopathol. 2005;20(1):299-315.
141. Song G, Ouyang G, Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9(1):59-71.
142. Bayascas JR, Alessi DR. Regulation of Akt/PKB Ser473 phosphorylation. Mol Cell. 2005;18(2):143-5.
143. Gao T, Furnari F, Newton AC. PHLPP: A phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 2005;18(1):13-24.
144. Chen WS, Xu P, Gottlob K, Chen M, Sokol K, Shiyanova T, Roninson I, Weng W, Suzuki R, Tobe K, Kadowaki T, Hay N. Growth retardation and increased apoptosis in mice with homozygous disruption of the akt1 gene. Genes Dev. 2001;15(312):2203-8.
145. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw EB, Kaestner KH, Bartolomei MS, Shulman GI, Birnbaum MJ. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science. 2001;292(5522):1728-31.
146. Warby SC, Chan EY, Metzler M, Gan L, Singaraja RR, Crocker SF, Robertson HA, Hayden MR. Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum Mol Genet. 2005;14(11):1569-77.
147. Ritch JJ, Valencia A, Alexander J, Sapp E, Gatune L, Sangrey GR, Sinha S, Scherber CM, Zeitlin S, Sadri-Vakili G, Irimia D, DiFiglia M, Kegel KB. Multiple phenotypes in Huntington disease mouse neural stem cells. Mol Cell Neurosci. 2012;50(1):70-81.
148. Gharami K, Xie Y, An JJ, Tonegawa S, Xu B. Brainderived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J Neurochem. 2008;105(2):369-79.
149. Saavedra A, García-Martínez JM, Xifró X, Giralt A, Torres-Peraza JF, Canals JM,Díaz-Hernández M, Lucas JJ, Alberch J, Pérez-Navarro E. PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum. Cell Death Differ. 2010;17(2):324-35.
150. Ransome MI, Hannan AJ. Impaired basal and runninginduced hippocampal neurogenesis coincides with reduced Akt signaling in adult R6/1 HD mice. Mol Cell Neurosci. 2013;54:93-107.
151. Simmons DA, Belichenko NP, Yang T, Condon C, Monbureau M, Shamloo M, Jing D, Massa SM, Longo FM. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. J Neurosci. 2013;33(48):18712-27.
152. XieY, Hayden MR, Xu B.BDNFoverexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci. 2010;30(44):14708-18.
153. Colin E, Zala D, Liot G, Rangone H, Borrell-Pagès M, Li X-J, Saudou F, Humbert S. Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J. 2008;27(15):2124-34.
154. Pineda JR, Pardo R, Zala D, Yu H, Humbert S, Saudou F. Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease. Mol Brain. 2009;2(1):33.
155. Pennuto M, Palazzolo I, Poletti A. Post-translational modifications of expanded polyglutamine proteins: Impact on neurotoxicity. Hum Mol Genet. 2009;18(R1):R40-7.
156. Manning BD, Cantley LC. AKT/PKB signaling: Navigating downstream. Cell. 2007;129(7):1261-74.
157. Varma H, Cheng R, Voisine C, Hart AC, Stockwell BR. Inhibitors of metabolism rescue cell death in Huntington's disease models. Proc Natl Acad Sci U S A. 2007;104(36):14525-30.
158. Kang M, Choi S, Jeong S-J, Lee S-A, Kwak TK, Kim H, Jung O, Lee M-S, Ko Y, Ryu J, Choi Y-J, Jeong D, Lee HJ, Ye S-K, Kim S-H, Lee JW. Cross-talk between TGF-1 and EGFR signalling pathways induces TM4SF5 expression and epithelial-mesenchymal transition. Biochem J. 2012; 443(3):691-700.
159. Song X, Thalacker FW, Nilsen-Hamilton M. Synergistic and multidimensional regulation Of plasminogen activator inhibitor type 1 expression by transforming growth factor Type and epidermal growth factor. J Biol Chem. 2012;287(15):12520-8.
160. Annunziata M, Granata R, Ghigo E. The IGF system. Acta Diabetol. 2011;48(1):1-9.
161. Rong J, McGuire JR, Fang Z-H, Sheng G, Shin J-Y, Li S-H, Li X-J. Regulation of intracellular trafficking of huntingtinassociated protein-1 is critical for TrkA protein levels and neurite outgrowth. J Neurosci. 2006;26(22):6019-30.
162. Conery AR, Cao Y, Thompson EA, Townsend CM, Ko TC, Luo K. Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol. 2004;6(4):366-72.
163. Remy I, Montmarquette A, Michnick SW. PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol. 2004;6(4):358-65.
164. Massague J. Smad transcription factors. Genes Dev. 2005;19(23):2783-810.
165. Song K, Cornelius SC, Reiss M, Danielpour D. Insulinlike growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2. J Biol Chem. 2003;278(40):38342-51.
166. Zuccato C, Marullo M, Conforti P, MacDonald ME, Tartari M, Cattaneo E. Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol. 2008;18(2):225-38.
167. Caja L, Sancho P, Bertran E, Fabregat I. Dissecting the effect of targeting the epidermal growth factor receptor on TGF-induced-apoptosis in human hepatocellular carcinoma cells. J Hepatol. 2011;55(2):351-8.
168. Massague J. Integration of Smad and MAPK pathways: A link and a linker revisited. Genes Dev. 2003;17(24):2993-7.
169. Jin X, Yin J, Kim S-H, Sohn Y-W, Beck S, Lim YC, Nam D-H, Choi Y-J, Kim H. EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res. 2011;71(22):7125-34.
170. Yamamura Y, Hua X, Bergelson S, Lodish HF. Critical role of Smads and AP-1 complex in transforming growth factorbeta-dependent apoptosis. J Biol Chem. 2000;275(46): 36295-302.
171. Battaglia G, Cannella M, Riozzi B, Orobello S, Maat-Schieman ML, Aronica E, Busceti CL, Ciarmiello A, Alberti S, Amico E, Sassone J, Sipione S, BrunoV, Frati L, Nicoletti F, Squitieri F. Early defect of transforming growth factor 1 formation in Huntington's disease. J Cell Mol Med. 2011;15(3):555-71.
172. An MC, Zhang N, Scott G, Montoro D,Wittkop T, Mooney S, Melov S, Ellerby LM. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell. 2012;253-63.
173. Kandasamy M, Couillard-Despres S, RaberKa, Stephan M, Lehner B,Winner B,Kohl Z, Rivera FJ, NguyenHP, Riess O, Bogdahn U, Winkler J, von Hörsten S, Aigner L. Stem cell quiescence in the hippocampal neurogenic niche is associated with elevated transforming growth factor-beta signaling in an animal model of Huntington disease. J Neuropathol Exp Neurol. 2010;69(7):717-28.
174. Haddad JJ. N-methyl-D-aspartate (NMDA) and the regulation of mitogen-activated protein kinase (MAPK) signaling pathways: A revolving neurochemical axis for therapeutic intervention? Prog Neurobiol. 2005;77(4):252-82.
175. Wang JQ, Fibuch EE, Mao L. Regulation of mitogenactivated protein kinases by glutamate receptors. J Neurochem. 2007;100(1):1-11.
176. Keshet Y, Seger R. The MAP kinase signaling cascades: A system of hundreds of components regulates a diverse array of physiological functions. Methods in Molecular Biology. 2010;661:3-38
177. Marshall CJ. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signalregulated kinase activation. Cell. 1995;80(2):179-85.
178. Weston CR,Davis RJ. TheJNKsignal transduction pathway. Curr Opin Genet Dev. 2002;12(1):14-21.
179. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev. 2001;81(2):807-69.
180. Sherman MY, Goldberg AL. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron. 2001;29(1):15-32.
181. Tammariello S, Landreth G, Estus S. The role of Jun kinase in apoptosis. In: Mattson M, Estus S, Rangnekar V, editors. Role in Disease, Pathogenesis and Prevention. Elsevier Science; 2001, pp. 197-214.
182. Dérijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T, Karin M, Davis RJ. JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell. 1994;76(6):1025-37.
183. Macián F, López-Rodríguez C, Rao A. Partners in transcription: NFAT and AP-1. Oncogene. 2001;20(19):2476-89.
184. Putcha GV, Moulder KL, Golden JP, Bouillet P, Adams JA, Strasser A, Johnson EM. Induction of BIM, a proapoptotic BH3-only BCL-2 family member, is critical for neuronal apoptosis. Neuron. 2001;29(3):615-28.
185. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron. 2001;29(3):629-43.
186. Morfini GA, You Y-M, Pollema SL, Kaminska A, Liu K, Yoshioka K, Björkblom B, Coffey ET, Bagnato C, Han D, Huang C-F, Banker G, Pigino G, Brady ST. Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat Neurosci. 2009;12(7): 864-71.
187. Antoniou X, Falconi M, Di Marino D, Borsello T. JNK3 as a therapeutic target for neurodegenerative diseases. J Alzheimer's Dis. 2011;24(4):633-42.
188. Resnick L, Fennell M. Targeting JNK3 for the treatment of neurodegenerative disorders. Drug Discov Today. 2004;9(21):932-9.
189. De Lemos L, Junyent F, Verdaguer E, Folch J, Romero R, Pallás M, Ferrer I, Auladell C, Camins A. Differences in activation of ERK1/2 and p38 kinase in Jnk3 null mice following KA treatment. J Neurochem. 2010;114(5):1315-22.
190. Yang DD, Kuan CY, Whitmarsh AJ, Rincón M, Zheng TS, Davis RJ, Rakic P, Flavell RA. Absence of excitotoxicityinduced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature. 1997;389(6653):865-70.
191. Junyent F, de Lemos L, Verdaguer E, Folch J, Ferrer I, Ortuño-Sahagún D, Beas-Zárate C, Romero R, Pallás M, Auladell C, Camins A. Gene expression profile in JNK3 null mice: A novel specific activation of the PI3K/AKT pathway. J Neurochem. 2011;117(2):244-52.
192. Kim S, Han J, Lee SK, Koo M, Cho DH, Bae SY, Choi M-Y, Kim JS, Kim J-H, Choe J-H, Yang J-H, Nam SJ, Lee JE. Smad7 acts as a negative regulator of the epidermal growth factor (EGF) signaling pathway in breast cancer cells. Cancer Lett. 2012;314(2):147-54.
193. Massagué J. TGF-beta signal transduction. Annu Rev Biochem. 1998;67:753-91.
194. Engel ME, Mcdonnell MA, Law BK, Moses HL. Interdependent SMAD and JNK signaling in transforming growth factor-mediated transcription interdependentSMADand JNK signaling in transforming growth factor mediated transcription. Cell Biol Metab. 1999;274(52):37413-20.
195. Yue J, Mulder KM. Requirement of Ras/MAPK pathway activation by transforming growth factor beta for transforming growth factor beta 1 production in a Smad-dependent pathway. J Biol Chem. 2000;275(40):30765-73.
196. Yu L, Hébert MC, Zhang YE. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 2002;21(14):3749-59.
197. Chang K-H, de Pablo Y, Lee H, Lee H, Smith MA, Shah K. Cdk5 is a major regulator of p38 cascade: Relevance to neurotoxicity in Alzheimer's disease. J Neurochem. 2010;113(5):1221-9.
198. Sun K, Lee H, Smith MA, Shah K. Direct and indirect roles of cyclin-dependent kinase 5 as an upstream regulator in the c-Jun NH 2-Terminal kinase cascade: Relevance to neurotoxic insults in Alzheimer's disease. Mol Biol Cell. 2009;20:4611-9.
199. Jebelli JD, Hooper C, Garden GA, Pocock JM. Emerging roles of p53 in glial cell function in health and disease. Glia. 2012;60(4):515-25.
200. Basu M, Bhattacharyya NP, Mohanty PK. Comparison of modules of wild type and mutant Huntingtin and TP53 protein interaction networks: Implications in biological processes and functions. PLoS One. 2013;8(5):e64838.
201. Fan J, Gladding CM, Wang L, Zhang LYJ, Kaufman AM, Milnerwood AJ, Raymond LA. P38 MAPK is involved in enhancedNMDAreceptor-dependent excitotoxicity inYAC transgenic mouse model of Huntington disease. Neurobiol Dis. 2012;45(3):999-1009.
202. Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, Cattaneo E, Hackam A, Sharp A, Thornberry N, Nicholson DW, Bredesen DE, Hayden MR. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem. 2000;275(26):19831-8.
203. Garcia M, Charvin D, Caboche J. Expanded huntingtin activates the c-Jun terminal kinase/c-Jun pathway prior to aggregate formation in striatal neurons in culture. Neuroscience. 2004;127(4):859-70.
204. Liu YF. Expression of polyglutamine-expanded Huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J Biol Chem. 1998;273(44):28873-7.
205. Liu YF, Dorow D, Marshall J. Activation of MLK2-mediated signaling cascades by polyglutamine-expanded huntingtin. J Biol Chem. 2000;275(25):19035-40.
206. Meriin AB, Mabuchi K, Gabai VL, Yaglom JA, Kazantsev A, Sherman MY. Intracellular aggregation of polypeptides with expanded polyglutamine domain is stimulated by stress-activated kinase MEKK1. J Cell Biol. 2001;153(4):851-64.
207. Perrin V, Dufour N, Raoul C, Hassig R, Brouillet E, Aebischer R, Luthi-Carter R, Deglon N. Implication of the JNK pathway in a rat model of Huntington's disease. Exp Neurol. 2009;215(1):191-200.
208. Gotoh I, Adachi M, Nishida E. Identification and characterization of a novel MAP kinase kinase kinase, MLTK. J Biol Chem. 2001;276(6):4276-86.
209. Gross EA, Callow MG, Waldbaum L, Thomas S, Ruggieri R. MRK, a mixed lineage kinase-related molecule that plays a role in gamma-radiation-induced cell cycle arrest. J Biol Chem. 2002;277(16):13873-82.
210. Dorow DS, Devereux L, Tu GF, Price G, Nicholl JK, Sutherland GR, Simpson RJ. Complete nucleotide sequence, expression, and chromosomal localisation of human mixedlineage kinase 2. Eur J Biochem. 1995;234(2):492-500.
211. Hirai S, Katoh M, Kyriakis JM, Zon LI, Rana A, Avruch J, Ohno S, Terada M. MST / MLK2, a Member of the mixed lineage kinase family, directly phosphorylates and activates SEK1, an MST / MLK2, a member of the mixed lineage kinase family, directly phosphorylates and activates SEK1, an activator of c-Jun N-terminal kinase. Enzymology. 1997;272(24):15167-73.
212. Cuenda A, Dorow DS. Differential activation of stressactivated protein kinase kinases SKK4/MKK7 and SKK1/MKK4 by the mixed-lineage kinase-2 and mitogenactivated protein kinase kinase (MKK) kinase-1. J Biochem. 1998;15:11-5.
213. Hirai S-I. Differential activation of two JNK activators, MKK7 and SEK1, by MKN28-derived nonreceptor serine/ threonine kinase/mixed lineage kinase 2. J Biol Chem. 1998;273(13):7406-12.
214. Merritt SE, Mata M, Zhu C, Hu X, Holzman LB, Nihalani D. The mixed lineage kinase DLK utilizes MKK7 and not MKK4 as substrate the mixed lineage kinase DLK utilizes MKK7 and not MKK4 as substrate. Cell Biol Metab. 1999;274(15):10195-202.
215. Nagata KI, Puls A, Futter C, Aspenstrom P, Schaefer E, Nakata T, Hirokawa N, Hall A. The MAP kinase kinase kinase MLK2 co-localizes with activated JNK along microtubules and associates with kinesin superfamily motor KIF3. EMBO J. 1998;17(1):149-58.
216. Kouroku Y, Fujita E, Jimbo A, Kikuchi T, Yamagata T, Momoi MY, Kominami E, Kuida K, Sakamaki K, Yonehara S, Momoi T. Polyglutamine aggregates stimulate ER stress signals and caspase-12 activation. Hum Mol Genet. 2002;11(13):1505-15.
217. Nishitoh H, Matsuzawa A, Tobiume K, Saegusa K, Takeda K, Inoue K, Hori S, Kakizuka A, Ichijo H. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev. 2002;16(11):1345-55.
218. Merienne K, Helmlinger D, Perkin GR, Devys D, Trottier Y. Polyglutamine expansion induces a protein-damaging stress connecting heat shock protein 70 to the JNK pathway. J Biol Chem. 2003;278(19):16957-67.
219. Lim MJ, Lin T, Jakowlew SB. Signaling mechanisms of transforming growth factor (TGF) in cancer: TGF induces apoptosis in lung cells by a Smad-dependent mechanism. In: ChengY, editor. Tumor Suppressor Genes. InTech; 2005, pp. 145-80.
220. Winograd-Katz SE, Levitzki A. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene. 2006;25(56):7381-90.
221. Holmberg CI, Tran SEF, Eriksson JE, Sistonen L. Multisite phosphorylation provides sophisticated regulation of transcription factors. Trends Biochem Sci. 2002;27(12):619-27.
222. Wang L, Ankati H, Akubathini SK, Balderamos M, Storey CA, Patel AV, Price V, Kretzschmar D, Bieh ER, D'Mello SR. Identification of novel 1,4-benzoxazine compounds that are protective in tissue culture and in vivo models of neurodegeneration. J Neurosci Res. 2010;88(9):1970-84.
223. Taylor DM, Moser R, Régulier E, Breuillaud L, Dixon M, Beesen AA, Elliston L, Silva Santos MDF, Kim J, Jones L, Goldstein DR, Ferrante RJ, Luthi-Carter R. MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition. J Neurosci. 2013;33(6):2313-25.
224. Yu Z, Li S, Evans J, Pillarisetti A, Li H, Li X. Mutant Huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease. J Neurosci. 2003;23(6):2193-202.
225. Rattray I, Smith E, Gale R, Matsumoto K, Bates GP, Modo M. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD. PLoS One. 2013;8(4): e60012.
226. Mangiarini L, SathasivamK, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3): 493-506.
227. Rangone Á, Poizat G, Troncoso J, Ross CA, Macdonald ME, Humbert S. The serum-and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci. 2004;19:273-9.
228. Patterson KI, Brummer T, Brien PMO, Daly RJ. Dualspecificity phosphatases: Critical regulators with diverse cellular targets. J Biochem. 2009;489:475-89.
229. Luthi-Carter R, Hanson SA, Strand AD, Bergstrom DA, Chun W, Peters NL, Woods AM, Chan EY, Kooperberg C, Krainc D, Young AB, Tapscott SJ, Olson JM. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: Parallel changes in muscle and brain. Hum Mol Genet. 2002;11(17):1911-26.
230. Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi M a, Sathasivam K, Cha J-HJ, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M, Augood SJ, Faull RLM, Olson JM, Bates GP, Jones L, Luthi-Carter R. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet. 2007;16(15):1845-61.
231. Jeannetau F, Deinhardt K, Miyoshi G, Bennett AM, Chao MV. The MAP kinase phosphatase, MKP-1, regulates BDNF-induced axon branching. Nat Neurosci. 2010;13(11):1373-9.
232. Steffan JS, Bodai L, Pallos J, Poelman M, Mccampbell A, Apostol BL, Kazantsev A, Schmidt E, Zhu Y, Greenwald M, Kurokawa R, Housman DE, Jackson GR, Marsh JL, Thompson LM. Histone deacetylase inhibitors arrest neurodegeneration in Drosophila. Nature. 2001;413:739-43.
233. Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-carter R, Hersch SM. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci. 2003;23(28):9418-27.
234. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-10.
235. Chang JR, Ghafouri M, Mukerjee R, Bagashev A, Chabrashvili T, Sawaya BE. Role of p53 in neurodegenerative diseases. Neurodegener Dis. 2012;9(2):68-80.
236. Yaun J, Luo K, Zhang L, Cheville J, Lou Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell. 2010;140(3):384-404.
237. Zacchi P, Gostissa M, Uchida T, Salvagno C, Avolio F, Volinia S, Ronai Z, Blandino G, Schneider C, Del Sal G. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature. 2002;419(6909):853-7.
238. Zheng H, You H, Zhou XZ, Murray SA. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature. 2002;419:849-54.
239. Mantovani F, Tocco F, Girardini J, Smith P, Gasco M, Lu X, Crook T, Del Sal G. The prolyl isomerase Pin1 orchestrates p53 acetylation and dissociation from the apoptosis inhibitor iASPP. Nat Struct Mol Biol. 2007;14(10):912-20.
240. Grison A, Mantovani F, Comel A, Agostoni E, Gustincich S, Persichetti F, Del Sal G. Ser46 phosphorylation and prolyl-isomerase Pin1-mediated isomerization of p53 are key events in p53-dependent apoptosis induced by mutant huntingtin. Proc Natl Acad SciUSA. 2011;108(44):17979-84.
241. Erickson JD, Bazan NG. The nucleolus fine-tunes the orchestration of an early neuroprotection response in neurodegeneration. Cell Death Differ. 2013;20(11):1435-7.
242. Mayo LD, Donner DB.Aphosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A. 2001;98(20):11598-603.
243. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B, Hung M. HER-2/neu induces P53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol. 2001;3:973-82.
244. Jordan J, Galindo F, Prehn JHM,Weichselbaum RR, Beckett M, Ghadge GD, Roos RP, Leiden JM, Miller RJ. p53 expression induces apoptosis in hippocampal pyramidal neuron cultures. J Neurosci. 1997;17(4):1397-405.
245. Morrison RS, Schwartzkroin PA, Jurgen H, Donehower A. Loss of the p53 tumor suppressor cell death gene protects neurons from kainate-induced cell death. J Neurosci. 1996;16(4):1337-45.
246. Sipione S, Rigamonti D, Valenza M, Zuccato C, Conti L, Pritchard J,KooperbergC, Olson JM, Cattaneo E. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet. 2002;11(17):1953-65.
247. Mayo LD, Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar CK, Donner DB. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem. 2005;280(28):25953-9.
248. Bae B-I, Xu H, Igarashi S, Fujimuro M, Agrawal N, Taya Y, Hayward SD, Moran TH, Montell C, Ross C a, Snyder SH, Sawa A. p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron. 2005;47(1):29-41.
249. Guo X, Disatnik M, Monbureau M, Shamloo M, Mochlyrosen D, Qi X. Inhibition of mitochondrial fragmentation diminishes Huntington ' s disease-associated neurodegeneration. J Clin Invest. 2013;123(12):5371-88.
250. Ghose J, Sinha M, Das E, Jana NR, Bhattacharyya NP. Regulation of miR-146a by RelA/NFkB and p53 in STHdh(Q111)/Hdh(Q111) cells, a cell model of Huntington's disease. PLoS One. 2011;6(8):e23837.
251. Kreiner G, Bierhoff H, Armentano M, Rodriguez-Parkitna J, Sowodniok K, Naranjo JR, Bonfanti L, Liss B, Schütz G, Grummt I, Parlato R. A neuroprotective phase precedes striatal degeneration upon nucleolar stress. Cell Death Differ. 2013;20(11):1455-64.
252. Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A. 2000;97(12): 6763-8.
253. Benn CL, Sun T, Sadri-Vakili G, McFarland KN, DiRocco DP,Yohrling GJ, ClarkTW, Bouzou B, Cha J-HJ. Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci. 2008;28(42):10720-33.
254. Suhr ST, Senut MC, Whitelegge JP, Faull KF, Cuizon DB, Gage FH. Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression. J Cell Biol. 2001;153(2):283-94.
255. Feng Z, Jin S, Zupnick a, Hoh J, de Stanchina E, Lowe S, Prives C, Levine AJ. P53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene. 2006;25(1):1-7.
256. Ryan AB, Zeitlin SO, Scrable H. Genetic interaction between expanded murine Hdh alleles and p53 reveal deleterious effects of p53 on Huntington's disease pathogenesis. Neurobiol Dis. 2006;24(2):419-27.
257. Rubinsztein DC. The roles of intracellular proteindegradation pathways in neurodegeneration. Nature. 2006;443(7113):780-6.
258. Glass CK, Saijo K, Winner B, Marchetto MC, Gage H. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918-34.
259. Träger U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S, McKinnon C, Sirinathsinghji E, Kahlon S, Pfister EL, Moser R, Hummerich H, Antoniou M, Bates GP, Luthi-Carter R, Lowdell MW, Björkqvist M, Ostroff GR, Aronin N, Tabrizi SJ. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain. 2014;137(Pt 3):819-33.
260. Franciosi S, Ryu JK, Shim Y, Hill A, Connolly C, Hayden MR, McLarnon JG, Leavitt BR. Age-dependent neurovascular abnormalities and altered microglial morphology in theYAC128 mouse model of Huntington disease. Neurobiol Dis. 2012;45(1):438-49.
261. Karin M, Ben-neriah Y. Phosphorylation meets ubiquitination: The control of NF-kappaB activity. Annu Rev Immunol. 2000;18:621-63.
262. Baldwin AS. The NF-κB and IκB proteins: New discoveries and insights. Annu Rev Immunol. 1996;14:649-81.
263. Häcker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE. 2006;357:re13.
264. Kane LP, Shapiro VS, Stokoe D,Weiss A. Induction of NFkB by the AKT/PKB kinase. Curr Biol. 1999;9:601-4.
265. Ozes ON, Mayo LD, Gustin J a, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999;401(6748):82-5.
266. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401(6748):86-90.
267. Madrid LV, Wang CY, Guttridge DC, Schottelius AJ, Baldwin AS, MayoMW. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NFkappaB. Mol Cell Biol. 2000;20(5):1626-38.
268. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS. Akt-dependent regulation of NF-kB is controlled bymTORand Raptor in association with IKK. Genes Dev. 2008;22:1490-500.
269. Ghosh S, MayMJ, Kopp EB. NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225-60.
270. Ghosh S, Karin M, Haven N. Missing pieces in the NF-kB puzzle. Cell. 2002;109:81-96.
271. Khoshnan A, Ko J, Tescu S, Brundin P, Patterson PH. IKKalpha and IKKbeta regulation of DNA damage-induced cleavage of huntingtin. PLoS One. 2009;4(6):e5768.
272. Mattson MP, Camandola S. NF-κ B in neuronal plasticity and neurodegenerative disorders. J Clin Invest. 2001;107(3):247-54.
273. HuangW-C, JuT-K, Hung M-C, Chen C-C. Phosphorylation of CBP by IKK promotes cell growth by switching the binding preference of CBP from p53 to NF-κB. Mol Cell. 2007;26(1):75-87.
274. Chariot A. The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol. 2009;19(8):404-13.
275. Li Q, Lu Q, Bottero V, Estepa G, Morrison L, Mercurio F, Verma IM. Enhanced NF-kappaB activation and cellular function in macrophages lacking IkappaB kinase 1 (IKK1). Proc Natl Acad Sci U S A. 2005;102(35):12425-30.
276. Lubin FD, Sweatt JD. The IκB kinase regulates chromatin structure during reconsolidation of conditioned fear memories. Neuron. 2008;55(6):942-57.
277. Khoshnan A, Ko J,Watkin EE, Paige LA, Reinhart PH, Patterson PH. Activation of the IkB Kinase complex and nuclear Factor-kB contributes to mutant huntingtin neurotoxicity. J Neurosci. 2004;24(37):7999-8008.
278. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, Ghosh S, Mosley RL, Gendelman HE, Pahan K. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A. 2007;104(47):18754-9.
279. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev. 2010;90(3):905-81.
280. Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y, Richards WG, Osmand A, Paganetti P, Bates GP. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem. 2010;285(12):8808-23.
281. Khoshnan A, Ko J, Patterson PH. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci U S A. 2002;99(2):1002-7.
282. Cho I-H, Hong J, Suh EC, Kim JH, Lee H, Lee JE, Lee S, Kim C-H, Kim DW, Jo E-K, Lee KE, Karin M, Lee SJ. Role of microglial IKKbeta in kainic acid-induced hippocampal neuronal cell death. Brain. 2008;131:3019-33.
283. Jia H, Kast RJ, Steffan JS, Thomas EA. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: Implications for the ubiquitinproteasomal and autophagy systems. Hum Mol Genet. 2012;21(24):5280-93.
284. Caron NS, Desmond CR, Xia J, Truant R. Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin. Proc Natl Acad Sci U S A. 2013;110(36):14610-5.
285. Witt J, Barisic S, Schumann E, Allgöwer F, Sawodny O, Sauter T,Kulms D. Mechanism of PP2A-mediated IKK beta dephosphorylation: A systems biological approach. BMC Syst Biol. 2009;3:71.
286. Metzler M, Gan L, Mazarei G, Graham RK, Liu L, Bissada N, Lu G, Leavitt BR, Hayden MR. Phosphorylation of Huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons fromNMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J Neurosci. 2010;30(43):14318-29.
287. Reijonen S, Kukkonen JP, Hyrskyluoto A, Kivinen J, Kairisalo M, TakeiN, Lindholm D,Korhonen L. Downregulation of NF-kappaB signaling by mutant huntingtin proteins induces oxidative stress and cell death. Cell Mol Life Sci. 2010;67(11):1929-41.
288. Hyrskyluoto A, Pulli I, Törnqvist K, Ho TH, Korhonen L, Lindholm D. Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: Involvement of calpastatin and the NF-κB pathway. Cell Death Dis. 2013;4:e646.
289. Di Pardo A, Alberti S, Maglione V, Amico E, Cortes EP, Elifani F, Battaglia G, Busceti CL, Nicoletti F, Vonsattel JPG, Squitieri F. Changes of peripheral TGF-1 depend on monocytes-derived macrophages in Huntington disease. Mol Brain. 2013;6:55.
290. Cao S, Zhang X, Edwards JP, Mosser DM. NF-κB1 (p50) homodimers differentially regulate pro-and antiinflammatory cytokines in macrophages. J Biol Chem. 2006;281(36):26041-50.
291. Driessler F, Venstrom K, Sabat R, Asadullah K, Area B. Molecular mechanisms of interleukin-10-mediated inhibition of NF-k B activity: A role for p50. Clin Exp Immunol. 2004;135:64-73.
292. Goswami A, Dikshit P, Mishra A, Mulherkar S, Nukina N, Jana NR. Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem Biophys Res Commun. 2006;342(1):184-90.
293. Godavarthi SK, Narender D, Mishra A, Goswami A, Rao SNR, Nukina N, Jana NR. Induction of chemokines, MCP-1, and KC in the mutant huntingtin expressing neuronal cells because of proteasomal dysfunction. J Neurochem. 2009;108(3):787-95.
294. Subramaniam S, Unsicker K. ERK and cell death: ERK1/2 in neuronal death. FEBS J. 2010;277(1):22-9.
295. JiY, LuY,Yang F, ShenW,TangTT-T, Feng L, Duan S, Lu B. Acute and gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. Nat Neurosci. 2010;13(3):302-9.
296. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, Cattaneo E, MacDonald ME, Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet. 2000;9(19): 2799-809.